Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Century Therapeutics, Inc. - Common Stock (NQ:IPSC)

0.4185 +0.0294 (+7.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,327,209
Open 0.3774
Bid (Size) 0.4150 (49)
Ask (Size) 0.4300 (1)
Prev. Close 0.3891
Today's Range 0.3418 - 0.4489
52wk Range 0.3418 - 4.428
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga

Performance

YTD
-59.8%
-59.8%
1 Month
-31.2%
-31.2%
3 Month
-60.9%
-60.9%
6 Month
-70.1%
-70.1%
1 Year
-89.6%
-89.6%

More News

Read More
Demystifying Century Therapeutics: Insights From 4 Analyst Reviews
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
4 Analysts Have This To Say About Century Therapeutics
Via Benzinga
5 Analysts Assess Century Therapeutics: What You Need To Know
Via Benzinga
Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Stages Highest Single Day Move In 11 Months As Casdin Capital Bumps Its Stake To 5.4%
Via Benzinga
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer
From Century Therapeutics, Inc.
Via GlobeNewswire
Robinhood To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
IPSC Stock Earnings: Century Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
IPSC Stock Earnings: Century Therapeutics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
From Century Therapeutics, Inc.
Via GlobeNewswire
Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing
Via Benzinga
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
From Century Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Century Therapeutics, Inc. - Common Stock publicly traded?
Yes, Century Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Century Therapeutics, Inc. - Common Stock trade on?
Century Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Century Therapeutics, Inc. - Common Stock?
The ticker symbol for Century Therapeutics, Inc. - Common Stock is IPSC on the Nasdaq Stock Market
What is the current price of Century Therapeutics, Inc. - Common Stock?
The current price of Century Therapeutics, Inc. - Common Stock is 0.4185
When was Century Therapeutics, Inc. - Common Stock last traded?
The last trade of Century Therapeutics, Inc. - Common Stock was at 04/09/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.